Although JAK inhibitors are in use for the treatment of rheumatoid arthritis and other inflammatory diseases (29, 30), it must be emphasized that JAKs do not selectively inhibit IL-6 signaling pathway and off-target effects may interfere with other cytokines or growth factors that utilize JAK/STAT pathway (28). This evidence concerns the gene IL6 and rheumatoid arthritis.